Intra-Cellular Therapies, Inc. and Arrowhead Pharmaceuticals, Inc.: SG&A Spending Patterns Compared

SG&A Spending Patterns: A Tale of Two Biotech Innovators

In the dynamic world of biotechnology, understanding the financial strategies of leading companies can offer valuable insights. Over the past decade, Intra-Cellular Therapies, Inc. and Arrowhead Pharmaceuticals, Inc. have demonstrated distinct trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Intra-Cellular Therapies saw a staggering increase in SG&A spending, peaking at approximately 410% of their 2014 levels by 2023. This reflects their aggressive expansion and investment in operational capabilities. In contrast, Arrowhead Pharmaceuticals exhibited a more moderate growth, with their SG&A expenses increasing by around 300% over the same period. Notably, 2022 marked a significant year for both companies, with Intra-Cellular Therapies reaching their highest SG&A expenditure, while Arrowhead Pharmaceuticals also saw a substantial rise. These patterns highlight the strategic priorities of each company as they navigate the competitive biotech landscape.